Arbutus Biopharma (ABUS) Cash & Equivalents (2010 - 2026)

Arbutus Biopharma has disclosed Cash & Equivalents across 17 years of filings, most recently posting $14.5 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $14.5 million, down 45.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.5 million (down 45.08% YoY), and the FY2025 annual result was $10.2 million, down 71.87% from the prior year.
• Cash & Equivalents came in at $14.5 million for Q1 2026 at Arbutus Biopharma, up from $10.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $81.3 million in Q1 2022 to a low of $10.2 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $30.8 million (2022), against an average of $34.1 million.
• Across the five-year window, Cash & Equivalents surged 130.86% in 2024 and plunged 71.87% in 2025, its largest moves.
• Arbutus Biopharma's Cash & Equivalents stood at $30.8 million in 2022, then retreated by 14.59% to $26.3 million in 2023, then soared by 38.22% to $36.3 million in 2024, then slumped by 71.87% to $10.2 million in 2025, then surged by 41.78% to $14.5 million in 2026.
• The last three Cash & Equivalents figures came in at $14.5 million (Q1 2026), $10.2 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.